Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema [Phase 1, Phase 2]

View source ↗

Summary

A combined Phase 1/2 clinical trial evaluating RO7446603 alone or with aflibercept or faricimab in participants with diabetic macular edema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Aflibercept (Aflibercept)
• Faricimab (faricimab)
• RO7446603

Snippet

Sponsor: Genentech, Inc. | Conditions: Diabetic Macular Edema | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING